BRAF and melanoma: In addition to its influence on BRAF-mutant melanoma, binimetinib has synergistic antitumor clinical activity in tumors like melanoma harboring neuroblastoma-rat sarcoma (NRAS) mutations and Kirsten Rat Sarcoma viral oncogene (KRASm) NSCLCs [25, 35, 38–43].